

COFAC-Col: A Cervical Cancer Control Networking Initiative in Five French-Speaking African Countries

Nicolas Berthet¹, Christine Berling², Hermann Nabi², Gisèle Woto Gaye³, Coumba Toure Kane³, Halimatou Diop-Ndiaye³, Ismaël Hervé Koumakpayi⁴, Corine Engohan Aloghe⁴, Ulrick Bisvigou⁴, Judith Didi Coulibaly⁵, Hortense Faye Kette⁶, Emmanuel Koffi⁵, Daniel Ekra⁷, Pamela Moussavou Boundzanga¹, Ingrid Labouba¹, Richard NJouom⁸, Pierre Marie Tebeu⁹, Isaac Sandjong⁹, Paul Adrien Atangana⁸, Blaise N'Kegoum⁹, Mala Rakoto-Andrianarivelo¹⁰, Fetra Angelot Rakotomalala¹⁰, Nantenaina Randrianajafisamindrakotroka¹¹, Tsitohery Francine Andriamampionona¹², Andy Ratovohery¹⁰, Xavier Sastre-Garau¹³, and Mamadou Diop³

Cancer is a global issue with significant disparities in the way it affects populations within and across countries. Cervical cancer disproportionately affects the poorest regions of the world. It is the leading cause of cancer-related death for women living in sub-Saharan Africa (1–3). Cervical cancer control is among the priorities of the World Health Organization which leads the Global Action Plan 2013–2020 for the prevention and control of noncommunicable diseases (4). Recent policy documents and guidelines have recommended state-of-the-art prevention and control methods of cervical cancer (5). These include visual inspection of the cervix, "Pap" smears, HPV testing, HPV vaccination, and early treatment (6, 7). Research is needed to build base of evidence and support the delivery of these methods and their implementation.

The African Consortium on Cervical Cancer Control Research (COFAC-Col) was launched during AORTIC 2013 by five French-speaking African countries (Senegal, Ivory Coast, Cameroon, Gabon, and Madagascar). INCa, France's National Cancer Institute, acted as a catalyst and currently supports the network's research activities. The primary goal of COFAC-Col is

to provide a working model to implement standardized high-quality research protocols across the five countries and share knowledge. The current focus is on identifying the nature of the HPV genotypes associated with high-grade intraepithelial neoplasia lesions and invasive cancers in a series of a minimum of 370 significant cases per country. This should provide a robust baseline for future evaluations of vaccine effectiveness, by determining the prevalence of the two main genotypes involved in CC HPV16 and 18, as well as the prevalence of other HPV genotypes.

Pathologists, oncologists, virologists, and epidemiologists are involved in each of the COFAC-Col countries. This transdisciplinary network offers an opportunity for the transfer of methodologies and expertise as well as professional training. The participating laboratories have been upgraded for standard histologic preparations and coding of the cervical lesions. The HPV typing is conducted according to the predefined standard protocols. Multidisciplinary validation cases are conducted before they are encoded in a shared database. COFAC-Col is expected to result in a unique contribution to cancer control capacity building across the five countries. Results are expected by the end of 2016.

Closing the cancer divide is an equity imperative. There is a general sense that acting global makes a difference. Notwithstanding the challenges and limitations inherent in all collaborative process, we believe that the ambitious, yet realistic goals of COFAC-Col should help achieve sustainable solutions in cervical cancer control.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

In memory of Dr. Benedicte Contamin from *Centre d'Infectiologie Charles Mérieux* (Madagascar), deceased during the implementation of this project.

Received January 27, 2016; accepted February 1, 2016; published OnlineFirst March 23, 2016.

¹Department of Zoonosis and Emerging Diseases, International Medical Research Center of Franceville, Franceville, Gabon. ²Institut National du Cancer, Boulogne-Billancourt, France. ³Centre Hospitalier Universitaire Aristide Le Dantec, Dakar, Senegal. ⁴Cancer Institute of Libreville, Libreville, Gabon. ⁵Centre Hospitalier Universitaire de Treichville, Abidjan, Côte d'Ivoire. ⁶Institut Pasteur de Côte d'Ivoire, Mermoz, Abidjan, Côte d'Ivoire. ⁷Institut National d'Hygiène Publique, Abidjan, Côte d'Ivoire. ⁸Centre Pasteur du Cameroun, Yaoundé, Cameroun. ⁹Centre Hospitalier Universitaire de Yaoundé, Yaoundé, Cameroun. ¹⁰Centre d'Infectiologie Charles Mérieux, Université d'Antananarivo, Antananarivo, Madagascar. ¹¹Centre Hospitalier Universitaire Joseph Ravoahangy Andrianavalona, Antananarivo, Madagascar. ¹²Centre Hospitalier Universitaire Tambohobe Fianarantsoa, Antananarivo, Madagascar. ¹³Institut de Cancérologie de Lorraine (ICL), Vandœuvre-lès-Nancy, Nancy, France.

Corresponding Author: Mamadou Diop, Hôpital Aristide Le Dantec, Dakar BP 15674, Senegal. Phone: 2217-7450-3945; Fax: 2217-7450-3945; E-mail: drmdiop@hotmail.com

doi: 10.1158/1055-9965.EPI-15-1248

©2016 American Association for Cancer Research.

References

1. Louie KS, de Sanjose S, Mayaud P. Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan

Africa: a comprehensive review. *Trop Med Int Health* 2009;14:1287–302.

2. GLOBOCAN. Cancer fact sheets, 2012 Cervical Cancer. Available from: <http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp>.
3. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. *Ann Oncol* 2011;22:2675–86.
4. World Health Organization (WHO)-led Global NCD Action Plan 2013–2020.
5. WHO Guide to essential practice—Comprehensive Cervical Cancer Control. 2nd ed.; 2014.
6. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. FUTURE I and II Study Group. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. *BMJ* 2012;344:e1401.
7. Roset Bahmanyar E, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, et al. HPV PATRICIA Study Group. Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. *Gynecol Oncol* 2012;127:440–50.